Abstract 4366830: Symptoms of Bladder Incontinence Are Associated with Worse Functional Status and Quality of Life in Heart Failure with Preserved Ejection Fraction

A Anand Jain (UT Southwestern Medical Center, Dallas, Texas, United States) N Neil Keshvani (UT Southwestern Medical Center, Dallas, Texas, United States) A Alvin Chandra (UT Southwestern Medical Center, Dallas, Texas, United States) V Vinayak Subramanian (UT Southwestern Medical Center, Dallas, Texas, United States) L Lajjaben Patel (UT Southwestern Medical Center, Dallas, Texas, United States) S Sophia Shah (Sarfez Pharmaceuticals, Vienna, Virginia, United States) S Salim Shah (Sarfez Pharmaceuticals, Vienna, Virginia, United States) C Christopher Wilcox (Georgetown University, Washington, District of Columbia, United States) B Bertram Pitt (University of Michigan, Ann Arbor) A Ambarish Pandey

Abstract

Introduction: Heart failure with preserved ejection fraction (HFpEF) is a geriatric syndrome characterized by a high burden of frailty, sarcopenia, and physical dysfunction. Given this clinical phenotype, patients with HFpEF would be anticipated to demonstrate elevated rates of incontinence; however, the prevalence and burden of bladder symptoms in this population and their associations with quality of life and physical function remain poorly characterized. Methods: This single-center study included patients enrolled in a prospective HFpEF registry at UT Southwestern between 8/2023-5/2025. Participants completed the Bladder Condition Assessment Tool (BCAT), a 4-item questionnaire that ranges from 0 to 20, with higher scores indicating more severe symptoms of incontinence. Outcomes included health-related quality of life (Kansas City Cardiomyopathy Questionnaire [KCCQ-12]), physical function (Short Physical Performance Battery [SPPB]), 6-minute walk distance (6MWD), and frailty (Fried Frailty Scale). Participants were stratified by data-derived BCAT tertiles representing minimal (tertile 1), intermediate (tertile 2), and severe (tertile 3) symptoms of incontinence. Linear regression assessed unadjusted associations between BCAT scores and outcomes, with additional adjustment for age, sex, and BMI. Results: 193 participants (age 70±12 years; 77% female; 29% Black) were included. The median (IQR) BCAT scores for the minimal, intermediate, and severe symptom groups were 3 (2-4), 7 (6-9), and 13 (11-15), respectively. Across symptom severity groups, there were no significant differences in age, sex, race, or comorbidities, though BMI was higher with greater symptom severity (p=0.042). In unadjusted analysis, severe (vs minimal/intermediate) symptoms were associated with worse 6MWD (β: -70 m; p=0.002), KCCQ-12 scores (β: -11; p=0.011), frailty (β: 0.52; p=0.005), and SPPB (β: -1.3; p=0.015). After adjustment, severe (vs minimal/intermediate) symptoms remained significantly associated with worse 6MWD (aβ: -50 m; p=0.022), KCCQ-12 scores (aβ: -9.0; p=0.036), and frailty (aβ: 0.46; p=0.016), with a trend towards worse SPPB Score (aβ: -0.92; p=0.075). Discussion: Worse symptoms of incontinence were associated with poorer physical function, decreased quality of life, and greater frailty. Given the substantial burden of symptoms in this population, clinicians should assess for incontinence as part of comprehensive HFpEF care.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (10)

A

Anand Jain

UT Southwestern Medical Center, Dallas, Texas, United States

N

Neil Keshvani

UT Southwestern Medical Center, Dallas, Texas, United States

A

Alvin Chandra

UT Southwestern Medical Center, Dallas, Texas, United States

V

Vinayak Subramanian

UT Southwestern Medical Center, Dallas, Texas, United States

L

Lajjaben Patel

UT Southwestern Medical Center, Dallas, Texas, United States

S

Sophia Shah

Sarfez Pharmaceuticals, Vienna, Virginia, United States

S

Salim Shah

Sarfez Pharmaceuticals, Vienna, Virginia, United States

C

Christopher Wilcox

Georgetown University, Washington, District of Columbia, United States

B

Bertram Pitt

University of Michigan, Ann Arbor

A

Ambarish Pandey